[Progress on biologic therapies for severe asthma].

Biologics play a critical role in the treatment of severe bronchial asthma. Both Global initiative for asthma (GINA) and Guidelines for the prevention and management of bronchial asthma in our country recommend currently approved biologics as add-on therapies for patients whose symptoms remain uncontrolled despite high dose maintenance ICS-LABA treatments. The approved biologics include Omalizumab, Mepolizumab, Benralizumab, Reslizumab, Dupilumab, and Tezepelumab. These agents exert anti-inflammatory effects in asthma by targeting immunoglobulin E (IgE), interleukin-5 (IL-5) and its receptor IL-5R, IL-4Rα, and thymic stromal lymphopoietin (TSLP), respectively. This review categorized biologics based on their therapeutic targets, summarized those approved for severe asthma and briefly introduced agents currently under clinical investigation. It also discussed common challenges and future trends in biologic therapies. This review aimed to provide clinical and research insights for optimizing the application of biologics in asthma management.